Technological Offers

I-SOL: New broad-spectrum antiviral therapy

Description


Novel recombinant protein based on sIFNAR2 (I-SOL), a soluble isoform of IFN-β, which possesses antiviral activity.

IFN-ß is a cytokine that mediates a variety of biological responses, including antiviral, antiproliferative and immunomodulatory effects. As a result, I-SOL exhibits activity on its own producing the same responses that IFN-ß mediates.

Medical need

The development of broad-spectrum, highly effective antiviral agents is a crucial goal in virology and pharmacy. Current strategies focus on two main areas: targeting viral infectivity and modulating the host defense system. However, antiviral development faces challenges due to the parasitic nature of viruses, viral resistance to targeted compounds, and nonspecific side effects. There is a need to create new, more potent and less toxic antivirals for diseases for which no treatments are available.

Prevalence

Global prevalence in 2023 of the main viruses:
VIH:38M
Hepatitis B: 296M
Hepatitis C: 58M
HSV:4,000M
SARS-CoV-2: 700M (variable)

Market

Global antiviral drugs: $55,500M
By disease:
VIH: $28,000M
Hepatitis: $15,000M
HSV: $5,000M
SARS-CoV-2: $3,000M

Other solutions

More than 4,000 antiviral drugs on the market, of which only 459 are on sale in Spain.

Results

The antiviral activity has been tested by bioassay in three independent laboratories. Currently, more than 40 tests have been performed to validate the activity on different viruses, such as: HIV, SARS-CoV-2 or respiratory syncytial virus.

In vitro and in vivo toxicity studies are also available.

Therapy


IBIMA Plataforma BIONAND inventors


BEGOÑA OLIVER MARTOS
Research group of IBIMA involved: C-01

ISAAC HURTADO GUERRERO
Research group of IBIMA involved: C-06

JOSÉ PAVÍA MOLINA
Research group of IBIMA involved: C-01

Contact


Innovation and Technology Transfer Office of IBIMA Plataforma BIONAND

transferencia@ibima.eu